Publications

• Merav Sendowski and Brahm H Segal Commentary on “Hospital Acquired Infections in the Oncology Patient”, in press.
  
  
• Srinivasan S, Takeshita K, Holkova B, Czuczman MS, Bernstein ZP, Miller K, Driscoll D, Chanan-Khan A, Clinical characteristics of gastrointestinal lymphomas associated with AIDS (GI-ARL) and the impact of highly active antiretroviral therapy (HAART). HIV Clinical Trials. In Press.
  
  
• Benekli M, Hahn T, Shafi F, Qureshi A, Alam AR, Czuczman MS, Bernstein ZP, Chanan-Khan Aa, Becker JL,
  
  
• McCarthy PL. Effect of rituximab on peripheral blood stem cell mobilization and engratment kinetics in non-Hodgkin's lymphoma patients. Bone Marrow Transplant 32(2):139-143, 2003.
  
  
• Hahn T, Rondeau C, Shaukat A, Jupudy V, Miller A, Alam AR, Baer MR, Bambach B, Bernstein Z, Chanan-Khan A, Czuczman M, Slack J, Wetzler M, Mookerjee B, Silva J, McCarthy PL. Acute renal failure requiring dialysis after allogenic blood and marrow transplantation identifies very poor prognosis patients. Bone Marrow Transplant 32: 405-410, 2003.
  
  
• Bernstein ZP , Brooks SP, Chanan-Khan A, Gollnick SO, Gilbert MJ, Tomasi TB. The Restoration of Allo-stimulatory
  
  
• Function to Accessory Cells in Patients with AIDS In Vitro and In Vivo by Granulocyte Macrophage – Colony
  
  
• Stimulating Factor (GM-CSF). HIV Clinical Trials 3(3): 219-224, 2002.
  
  
• Bernstein Z, Chanan-Khan A,Miller KC, Northfelt D, The Kaposi’s Sarcoma Study Group, Lopez-Berestein G, Gill PA.
  
  
• A multicenter phase II study of the intravenous administration of ATRAGEN in patients with AIDS-associated Kaposi’s sarcoma. Cancer 95(12):2555-2561, 2002.
  
  
• Czuczman MS, Fallon A, Mohr A, Stewart C, Bernstein ZP, McCarthy P, Skipper M, Brown K, Miller K, Wentling D, Klippenstein D, Loud P, Rock MK, Benyunes M, Grillo-Lopez AJ, Bernstein SH. Rituximab in combination with CHOP or Fludarabine in low-grade lymphoma. Seminars in Oncology 29(1) (suppl 2): 36-40, 2002.
  
  
• Sendowski M , Bepler G: Chemoprevention for lung cancer. Oncology Spectrums 3”116-126, 2002.
  
  
• Francisco J Hernandez-Ilizaliturri and Merav SendowskiRecent Advances in the Molecular Biology of Non-Hodgkin’s Lymphoma Fellow Reporter Vol. 6, No. 4, June 2001.
  
  
• Hernandez-Ilizaliturri FJ and Sendowski M: Recent advances in the molecular biology of non-Hodgkin’s lymphoma. Fellow reporter 6: 36-42, 2001.
  
  
• Khushalani NI, Bakri FG, Wentling D, Brown K, Mohr A, Anderson B, Keesler C, Ball D, Bernstein, ZP, Bernstein SH, Czuczman MS, Segal BH, McCarthy PL. Respiratory syncytial virus infection in the late bone marrow transplant period: report of three cases and review. Bone Marrow Transplantation 27:1071-1073, 2001.
  
  
• Shastri KA. HO C. Logue GL. An aquired factor V inhibitor: clinical and laboratory features. Journal of Medicine. 30(5-6):357-66, 1999
  
  
• Tornatore KM. Venuto RC. Logue GL. Davis PJ CD4+ and CD8+ lymphocyte and cortisol response patterns in elderly and young males after methylprednisolone. Journal of Medicine. 29(3-4):159-83, 1998.
  
  
• Shastri KA, Logue GL, Lehman R, Stern MP, Raza S. Complement activation by heparin-protamine complexes during cardiopulmonary bypass: Effect of C4A null allele. J of Thoracic and Cardiovasc Surg, 114:482-8 1997
  
  
• Logue GL and Wear SE: A Desperate Solution: Individual Autonomy and Double-Blind Controlled Experiments. Journal of Medicine and Philosophy, Vol 20, No 1 , pp 57-64 1995.
  
  
• Wear SE and Logue GL: The Problem of Medical Futility: Falling Back on a Preventive Ethics Approach, Journal of Clinical Ethics, Vol 6, No 1 , pp. 138-148 1995.
  
  
• Shastri KA, Logue GL, Stern MP, Raza S, Logue GL, O’Connor BM, Bovill JJ and Hoover EL. Neutrophil lactoferrin release during open heart surgery is unrelated to complement activation. ASAIO Journal, 40:56-61, 1994.
  
  
• Tornatore KM, Logue GL, Venuto RC, Davis PJ: Pharmacokinetics of Methylprednisolone in Elderly and Young Healthy Males. Journal of American Geriatrics Society, 42:1118-1122, 1994.
  
  
• Wear S, Lagaipa S, Logue GL: Toleration of moral diversity and the conscientious refusal by physicians to withdraw life-sustaining treatment. The Journal of Medicine and Philosophy 19:147-159, 1994.
  
  
• Wear SE and Logue GL: Policy Options When an Attending Physician Refuses to Honor a Legally Enforceable Demand to Withdraw Life-Sustaining Treatment. VA National Center for Clinical Ethics News, Vol. 2, No. 4 , pp 1-2, 9, 11 1994.
  
  
•  Shastri K, Stern M, Lehman S, Logue GL, Colby J, Raza S. Increased Complement Activation by Heparin Protamine Interaction During Open Heart Surgery in Patients with Heterogygous C4A Deficiency: #2139 Blood 86: suppl. 1, 1995.
  
  
• Vidal C, Yu Wong, Pendleton J, Shastri K, and Logue GL. Successful Treatment of Felty’s Syndrome with Granulocyte-Colony Stimulating Factor (G-CSF) complicated with exacerbation of Rheumatoid Arthritis. #2236 Blood 84:suppl. 1, 1994.